S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Panbela Therapeutics (PBLA) Competitors

$1.12
+0.01 (+0.90%)
(As of 02/23/2024 ET)

PBLA vs. KTRA, AVTX, DMK, SCPS, CALA, SPRC, REVB, BLPH, GRI, and GLMD

Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Kintara Therapeutics (KTRA), Avalo Therapeutics (AVTX), DMK Pharmaceuticals (DMK), Scopus BioPharma (SCPS), Calithera Biosciences (CALA), SciSparc (SPRC), Revelation Biosciences (REVB), Bellerophon Therapeutics (BLPH), GRI Bio (GRI), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical preparations" industry.

Panbela Therapeutics vs.

Kintara Therapeutics (NASDAQ:KTRA) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Company Net Margins Return on Equity Return on Assets
Kintara TherapeuticsN/A N/A -305.69%
Panbela Therapeutics N/A N/A -182.13%

Panbela Therapeutics has a consensus target price of $500.00, indicating a potential upside of 44,542.86%. Given Kintara Therapeutics' higher possible upside, analysts clearly believe Panbela Therapeutics is more favorable than Kintara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kintara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Panbela Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kintara Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

In the previous week, Kintara Therapeutics had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 2 mentions for Kintara Therapeutics and 1 mentions for Panbela Therapeutics. Panbela Therapeutics' average media sentiment score of 0.00 equaled Kintara Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kintara Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Panbela Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kintara Therapeutics and Panbela Therapeutics both received 16 outperform votes by MarketBeat users. However, 88.89% of users gave Kintara Therapeutics an outperform vote while only 66.67% of users gave Panbela Therapeutics an outperform vote.

CompanyUnderperformOutperform
Kintara TherapeuticsOutperform Votes
16
88.89%
Underperform Votes
2
11.11%
Panbela TherapeuticsOutperform Votes
16
66.67%
Underperform Votes
8
33.33%

2.4% of Kintara Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Panbela Therapeutics shares are held by institutional investors. 4.3% of Kintara Therapeutics shares are held by company insiders. Comparatively, 0.1% of Panbela Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kintara Therapeutics is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kintara TherapeuticsN/AN/A-$14.65M-$5.96-0.02
Panbela TherapeuticsN/AN/A-$34.93M-$4.01 thousand0.00

Summary

Panbela Therapeutics beats Kintara Therapeutics on 6 of the 11 factors compared between the two stocks.


Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBLA vs. The Competition

MetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$291,000.00$6.70B$5.03B$7.52B
Dividend YieldN/A2.72%2.92%3.86%
P/E Ratio0.0010.83101.2616.11
Price / SalesN/A143.393,103.9555.29
Price / CashN/A18.1888.3852.42
Price / Book0.004.564.364.63
Net Income-$34.93M$156.18M$112.59M$207.21M
7 Day Performance-10.40%1.07%0.86%-0.98%
1 Month Performance-70.29%10.55%6.85%3.29%
1 Year Performance-99.85%1.27%8.77%3.69%

Panbela Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTRA
Kintara Therapeutics
0.2197 of 5 stars
$0.10
flat
N/A-98.1%$332,000.00N/A-0.022Gap Up
High Trading Volume
AVTX
Avalo Therapeutics
0 of 5 stars
$4.20
-5.8%
N/A-99.4%$357,000.00$2.25M-0.0120Positive News
Gap Up
DMK
DMK Pharmaceuticals
0 of 5 stars
$0.04
flat
$1.50
+3,404.7%
N/A$432,000.00$3.62M0.0011Gap Down
SCPS
Scopus BioPharma
0 of 5 stars
$0.00
flat
N/A-98.0%$151,000.00N/A0.0013
CALA
Calithera Biosciences
0 of 5 stars
$0.03
flat
N/A-70.5%$146,000.00$9.75M0.008
SPRC
SciSparc
0 of 5 stars
$4.02
+15.5%
N/A-84.5%$482,000.00$3.32M0.003Gap Up
High Trading Volume
REVB
Revelation Biosciences
0.0706 of 5 stars
$2.83
+2.2%
N/A-95.6%$594,000.00N/A-0.206
BLPH
Bellerophon Therapeutics
1.4592 of 5 stars
$0.05
flat
$2.00
+3,821.6%
-96.1%$624,000.00N/A-0.0618Gap Down
GRI
GRI Bio
0 of 5 stars
0.97
-6.7%
N/AN/A$630,000.00N/A-0.011Positive News
Gap Down
GLMD
Galmed Pharmaceuticals
0 of 5 stars
$0.38
-2.6%
N/A-95.8%$638,000.00N/A-0.104Analyst Report

Related Companies and Tools

This page (NASDAQ:PBLA) was last updated on 2/23/2024 by MarketBeat.com Staff